 STAT Transcription Factors
"STAT Transcription Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of transcription factors containing SH2 DOMAINS that are involved in CYTOKINE-mediated SIGNAL TRANSDUCTION. STAT transcription factors are recruited to the cytoplasmic region of CELL SURFACE RECEPTORS and are activated via PHOSPHORYLATION. Once activated they dimerize and translocate into the CELL NUCLEUS where they influence GENE expression. They play a role in regulating CELL GROWTH PROCESSES and CELL DIFFERENTIATION. STAT transcription factors are inhibited by SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS and PROTEIN INHIBITORS OF ACTIVATED STAT.
| Descriptor ID |
D050791
|
| MeSH Number(s) |
D12.644.360.024.342 D12.776.157.057.186 D12.776.476.024.421 D12.776.930.840
|
| Concept/Terms |
STAT Transcription Factors- STAT Transcription Factors
- Transcription Factors, STAT
- STAT (Signal Transducers and Activators of Transcription) Proteins
|
Below are MeSH descriptors whose meaning is more general than "STAT Transcription Factors".
Below are MeSH descriptors whose meaning is more specific than "STAT Transcription Factors".
This graph shows the total number of publications written about "STAT Transcription Factors" by people in UAMS Profiles by year, and whether "STAT Transcription Factors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2022 | 0 | 1 | 1 | | 2017 | 2 | 0 | 2 | | 2011 | 1 | 0 | 1 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "STAT Transcription Factors" by people in Profiles over the past ten years.
-
Yan MM, Li ZX, Chen C, Zhang W, Zhou DB. [Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Dec; 30(6):1741-1745.
-
de Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE, Colleoni GWB. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients. Cancer Lett. 2017 09 10; 403:206-215.
-
Wright F, Hammer M, Paul SM, Aouizerat BE, Kober KM, Conley YP, Cooper BA, Dunn LB, Levine JD, DEramo Melkus G, Miaskowski C. Inflammatory pathway genes associated with inter-individual variability in the trajectories of morning and evening fatigue in patients receiving chemotherapy. Cytokine. 2017 03; 91:187-210.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|